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Abstract
Introduction: Chemotherapy- induced neuropathies are one of the most common side 
effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunc-
tion. Chemotherapy effects on the nervous system vary between different classes of 
drugs and depend on specific chemical and physical properties of the drug used. The 
three most neurotoxic classes of anti- cancer drugs are: platinum- based drugs, taxanes, 
and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs 
are: bortezomib, ixabepilone, and vinca alkaloids.
Methods: Here, in this paper, based on our experience and current knowledge, we 
provide a short review of the most common, neuropathy- inducing anti- cancer drugs, 
describe the most prevalent neuropathy symptoms produced by each of them, and 
outline preventive measures and treatment guidelines for cancer patients suffering 
from neuropathy and for their health care providers.
Results: Patients should be encouraged to report any signs of neuropathic pain, altera-
tion in sensory perception, tingling, numbness, burning, increased hot/cold sensitivity 
and motor dysfunctions as early as possible. If known neurotoxic chemotherapeutics 
are used, a neurological examination with electrophysiological evaluation should be 
implemented early in the course of treatment so, both patients and physicians would 
be better prepared to cope with possible neurotoxic effects.
Conclusions: The use of neurotoxic chemotherapeutics should be closely monitored 
and if clinically permitted, that is, if a patient shows signs of cancer regression, drug 
doses should be reduced or combined with other less neurotoxic anti- cancer medica-
tion. If not counteractive, the use of over the counter antineuropathic supplements 
such as calcium or magnesium might be encouraged. If physically possible, patients 
should also be encouraged to exercise regularly and avoid factors that might increase 
nerve damage such as excessive drinking, smoking, or sitting in a cramped position.
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1  | INTRODUCTION
Every year, a large number of patients undergoing cancer treatment ex-
perience peripheral nerve dysfunction and symptoms of polyneuropathy. 
Distorted thermal sensation, pain and nerve damage are the most com-
mon and unpleasant side effects of chemotherapy, affecting treatment 
dosing, patient well- being, and quality of life and incurring additional 
costs on health care systems worldwide (Seretny et al., 2014).
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Chemotherapy- induced polyneuropathies are one of the most com-
mon side effects of cancer treatment, surpassing bone marrow sup-
pression and kidney dysfunction. The effects of chemotherapy on the 
nervous system vary between different classes of drugs and depend on 
specific chemical and physical properties of the drug used. Observed 
symptoms range from acute, transient thermal sensation to permanent, 
accumulative changes in peripheral nerves accompanied by chronic 
pain and irreversible nerve damage. These symptoms affect patient 
motor ability, often requiring extensive physical therapy and posing a 
heavy burden for health care providers (Lema, Foley, & Hausheer, 2010).
Chemotherapeutics exerting neurotoxic effects on the periph-
eral nervous system are often the ones that are also most commonly 
used, often listed as a standard, routine medication for most common 
types of cancer (WHO, 2014). Among them, the three most neurotoxic 
classes of anti- cancer drugs are: platinum- based drugs, taxanes, and 
thalidomide and its analogs; other, less neurotoxic but also commonly 
used drugs are: bortezomib, ixabepilone, and vinca alkaloids (Table 1).
Here, in this paper, we aim to provide a short review of the most 
common, neuropathy- inducing anti- cancer drugs, describe the most 
prevalent neuropathy symptoms produced by each of them, and out-
line preventive measures and treatment guidelines for cancer patients 
suffering from neuropathy and for their health care providers.
2  | PLATINUM- BASED DRUGS
Platinum- based drugs, sometimes referred as to platins, such as ox-
aliplatin, cisplatin, and carboplatin belong to a large class of synthetic 
anti- cancer drugs whose main antineoplastic action is triggered by 
DNA- cross- linking- inhibiting cancer cell DNA synthesis and repair 
(Kelland & Farrell, 2000). Platinum- based drugs are enlisted on the 
WHO Model List of Essential Medicines which represents the most 
important medications in a basic health system (WHO, 2014) and are 
used in the treatment of a variety of tumors, from lung and ovarian 
cancers to bladder, germ cell, testicular, and colorectal cancers.
Neurotoxicity is their main dose- limiting side effect and affects a 
large number of platin- treated patients, with neuropathy incidence rate 
ranging from 70% to 100% of all treated patients (McWhinney, Goldberg, 
& McLeod, 2009). These numbers make platinum- based drugs the most 
neurotoxic anti- cancer drugs available on market. Among platins, oxal-
iplatin evokes the most varied and unique neurotoxic effects, making it 
detrimental among available classes of anti- cancer drugs.
Platin- induced neurotoxic effects include dysesthesias, tingling, 
and burning sensation and neuropathic pain. Using electrophysiologi-
cal techniques, peripheral nerve changes are diagnosed as mononeu-
ropathies such as carpal tunnel syndrome or mild to severe sensory 
and sensorimotor polyneuropathies of axonal origin. Studies suggest 
that the neurotoxic effects are triggered by drug accumulation in the 
dorsal root ganglia, causing neuronal dysfunction and apoptosis, thus 
leading to long- term, often, irreversible changes in the peripheral ner-
vous system (Avan et al., 2015; Park et al., 2015).
In case of oxaliplatin, additional transient post IV infusion neu-
rotoxic effects have also been observed, which have often been de-
scribed as jaw tightening, eye pain, leg cramps, pseudolaryngospasm, 
and cold hypersensitivity. These symptoms usually occur 30–60 min 
post infusion and resolve within a couple of days (Argyriou et al., 2013; 
Avan et al., 2015). The mechanisms underlying these transient neu-
rotoxic effects remain unclear; however, recent studies indicate that 
they might be a direct result of structural properties of oxaliplatin. An 
oxalate, as part of the oxaliplatin chemical compound, released during 
oxaliplatin metabolism, binds to calcium through chelation, blocking 
calcium channels and altering neuronal signal transduction (Avan et al., 
2015; McWhinney et al., 2009).
3  | TAXANES
Taxanes are a class of diterpenoids and include: paclitaxel (Taxol), 
docetaxel (Taxotere), and cabazitaxel (Jevtana) that act on micro-
tubules, effectively preventing cancer cell division (Abal, Andreu, & 
Barasoain, 2003). Taxanes have been approved for use in a number of 
different types of cancer including, but not limited to: breast cancer, 
ovarian cancer, lung cancer, pancreatic cancer, and recently prostate 
cancer (cabazitaxel). Within that group, paclitaxel received the status 
of essential medicine on the WHO Model List of Essential Medicines 
(WHO, 2014). Despite their widespread use in cancer treatment, tax-
anes have a number of side effects, one of them being chemotherapy- 
induced polyneuropathy. Depending on the taxane used, neuropathy 
TABLE  1 Summarized characteristics of neurotoxicity- inducing drugs routinely used in cancer treatment. List of cancers treated is by no 
means exclusive, rather we point out to the most frequently treated cancers assigned to a given drug or a group of drugs
Drug name Types of cancer treated Mechanism of action Neuropathy incidence
Platinum- based drugs Lung, ovarian bladder, germ cells 
testicular, colorectal cancer
Cancer cell DNA- cross- linking Very high 70–100%
Taxanes Breast, ovarian, lung prostate, 
pancreatic cancer
Cancer cell microtubule formation 
impairment
High 11–87%
Thalidomide and its analogs Multiple myeloma Antiangiogenesis immunomodulation High 20–60%
Ixabepilone Breast cancer Tubulin malformation High 60–65%
Bortezomib Multiple myeloma Proteasome inhibition Moderate 20–30%
Vinca alkaloids Lung, brain, bladder testicular  
cancer
Cancer cell microtubule formation 
impairment
Moderate Up to 20%
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incidence ranges from 11% to 87%, the highest rates of which are re-
ported for paclitaxel (Park et al., 2014; Scripture, Figg, & Sparreboom, 
2006). Neurological symptoms include paresthesias and dysesthesias 
of toes, finger numbness, and loss of dexterity (Pace et al., 1997). 
Using electrophysiological techniques, patients were predominately 
diagnosed with moderate axonal sensory neuropathy; however, rare 
cases of sensorimotor polyneuropathy and carpal tunnel syndrome 
were observed as well (Vahdat et al., 2001). The mechanism of 
taxane- induced neurotoxicity remains elusive; however, growing evi-
dence indicates that a disturbance of axonal transport and neuronal 
oxidative stress might be the leading factors resulting in neuropathic 
changes in taxane- treated cancer patients (Shemesh & Spira, 2010).
4  | THALIDOMIDE AND ITS ANALOGS
Thalidomide (sold as Immunoprin, Talidex, Talizer, or Thalomid) and 
its synthetic analogs such as lenalidomide, pomalidomide, and apre-
milast belong to the family of antiangiogenic and immunomodulatory 
drugs used in multiple myeloma treatment (Hideshima et al., 2000).
Neurotoxic effects of thalidomide are predominately observed in 
lower extremities neuropathies, such as foot and leg dysesthesia, sen-
sory loss, tingling, impaired reflexes, and painful muscle cramps. Using 
electrophysiological techniques, thalidomide- induced neurotoxicity is 
observed as impaired nerve conduction velocity, altered amplitude, 
and H reflex absence and in the vast majority of patients is diagnosed 
as sensory or sensorimotor polyneuropathy of primarily axonal origin. 
It is estimated that thalidomide- induced polyneuropathy affects from 
20% to 60% of all thalidomide- treated cancer patients (Cavaletti et al., 
2004; Clemmensen, Olsen, & Andersen, 1984; Plasmati et al., 2007). 
The mechanism of thalidomide- induced neurotoxicity is not com-
pletely clear; however, studies suggest that it might be prompted by 
nuclear factor- kappaB- related dysregulation of neurotrophins that are 
critical for sensory neuron survival (Briani et al., 2004). Furthermore, 
growing evidence indicates that old age and pre- existing predispo-
sition to nerve diseases resulting from a polymorphism of genes 
involved in nerve repair might play a crucial role in developing a 
thalidomide- induced polyneuropathy (Johnson et al., 2011).
5  | BORTEZOMIB
Bortezomib (sold as Velcade or Cytomib) is a proteasome inhibitor used 
in multiple myeloma and mantle cell lymphoma treatment. It is a very po-
tent drug, often used when other antineoplastic agents fail (Chen, Frezza, 
Schmitt, Kanwar, & Dou, 2011; Richardson, Hideshima, & Anderson, 
2003). Peripheral nerve changes and polyneuropathy symptoms affect 
20–30% of all bortezomib- treated patients and are manifested as neu-
ropathic pain of toes and/or fingers, tingling and burning sensations, and 
muscle wasting. Electrophysiological studies show a slight decrease in 
motor and sensory nerve conduction velocity, H- reflex prolonged la-
tency and sensory potential low amplitude suggestive of either axonal 
or demyelination neuropathy (Carozzi et al., 2013; Corso et al., 2010; 
Thawani, Tanji, De Sousa, Weimer, & Brannagan, 2015). The mechanism 
of bortezomib- induced polyneuropathy remains elusive. Recent studies 
show that one plausible explanation of bortezomib neurotoxicity might 
be related to its antineoplastic activity targeted at mitochondria that 
might spread beyond cancer cells and affect neurons. Another possible 
explanation comes from studies of bortezomib action in cancerous cells, 
suggesting that its neurotoxicity might be a side effect of blocking NF- kB 
activation and subsequent inhibition of nerve growth factors required 
for neuronal survival. Finally, there is a body of evidence suggesting that 
bortezomib neurotoxicity might be triggered by inflammatory processes 
concomitant with neoplastic growth (Argyriou, Iconomou, & Kalofonos, 
2008; Meregalli, 2015). Surprisingly, studies showed that cancer ther-
apy involving both bortezomib and thalidomide reduced incidence of 
chemotherapy- induced neuropathies in cancer patients, suggesting 
that both substances might cancel each other’s neurotoxic activity in 
the course of treatment (Chaudhry, Cornblath, Polydefkis, Ferguson, & 
Borrello, 2008).
6  | IXABEPILONE
Ixabepilone (sold as Ixempra) is an analog of epothilone B and belongs to 
a relatively new class of anti- cancer epothilone drugs that act as tubulin 
destabilizers effectively preventing divisions of cancer cells. Ixabepilone 
is very potent, however, until now it has only been approved in the 
US, that is, not in Europe;  it is used in breast cancer patients not re-
sponding to other available chemotherapies (De Luca et al., 2015; Pivot 
et al., 2008). Evidence obtained from a large-scale clinical trial showed 
that 65% of all ixabepilone treated patients, demonstrated  symptoms 
of neuropathy. In most cases, neuropathies were reversible, mild, or 
moderate and mainly sensory in nature. Reported symptoms included 
neuropathic pain, dysesthesia, and neuralgia (Vahdat et al., 2012). As 
with other chemotherapeutics, the mechanisms underlying ixabepilone 
neurotoxicity remain unclear. Limited available evidence shows that ixa-
bepilone neurotoxicity might be due to increased deposits of the drug in 
peripheral neurons, triggering mitochondrial dysfunction and increased 
oxidative stress in affected neurons (Ebenezer et al., 2014).
7  | VINCA ALKALOIDS
Vinca alkaloids, such as vinblastine, vinorelbine, vincristine, and vin-
desine belong to a class of widely used plant- derived drugs used in 
the treatment of different types of cancers, including but not limited 
to lung, brain, bladder, and testicular cancer (O’Marcaigh & Betcher, 
1995). Among vinca alkaloids, vinblastine is the most commonly used 
anti- cancer drug, listed in the WHO Model List of Essential Medicines 
(WHO, 2014). Vinca alkaloids bind tubulin; thus, preventing microtu-
bule formation and inhibiting cancer cell division (Jordan, Thrower, 
& Wilson, 1991). Vinca alkaloids trigger neuropathy in about 20% of 
cancer patients; typical symptoms include lower limb weakness, sen-
sory impairment, altered gait, and diminished reflexes. Using electro-
physical techniques, nerve changes are diagnosed as predominantly 
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moderate to severe sensory or sensorimotor polyneuropathies (Ness 
et al., 2013). Mechanisms underlying neurotoxicity of vinca alkaloids 
remain unclear; however, available evidence suggests that genetic 
polymorphism of genes crucial for microtubule formation might play a 
role in developing neuropathy in cancer patients (Diouf et al., 2015).
8  | DIAGNOSTIC TECHNIQUES
Neurophysiological techniques and nerve biopsies are useful tools for 
diagnosis and assessment of functional nerve damage (Boruchow & 
Gibbons, 2013; Themistocleous, Ramirez, Serra, & Bennett, 2014). Skin 
biopsies have shown 88.4% diagnostic efficacy (Devigili et al., 2008). 
A standard skin punch biopsy 3 mm in diameter can be taken 10 cm 
proximal to the lateral malleolus (Lauria et al., 2010). Morphometric 
examination of epidermal and dermal nerves is very helpful, especially 
for investigating small nerve fiber abnormalities, inaccessible to neu-
rophysiological tests. Using immunohistochemical or immunofluores-
cent techniques, unmyelinated fibers innervating the epidermis and 
large myelinated fibers and autonomic fibers can be observed (Lauria, 
Lombardi, Camozzi, & Devigili, 2009).
Conventional nerve conduction velocity studies include the exam-
ination of large myelinated fibers; however, the main limitation of this 
method is its inability to detect changes in small fibers (Themistocleous 
et al., 2014).
Quantitative sensory testing is another noninvasive, standardized 
technique for psychophysical threshold evaluation of cold and warm 
sensations—thermal detection, pain thresholds, and stimuli- response 
function (Devigili et al., 2008; Themistocleous et al., 2014). Furthermore, 
this kind of testing can assess the function of thin and unmyelinated 
nerve fibers (Verberne, Wiggers, Vermeulen, & de Jong, 2013).
Furthermore, there are new diagnostic techniques such as the 
measurement of nerve fiber density using corneal confocal micros-
copy and nociceptive evoked potentials (Hoeijmakers, Faber, Lauria, 
Merkies, & Waxman, 2012). Nerve morphology can be assessed using 
in vivo corneal confocal microscopy, including corneal nerve fiber den-
sity, that is, the number of nerve fibers/mm2, corneal nerve branch 
density—the number of branch points in the main nerves/mm2 and 
corneal fiber length—the total length of nerves mm/mm2 (Ferdousi 
et al., 2015). In patients with chemotherapy- induced peripheral neu-
ropathy, using in vivo corneal confocal microscopy revealed an in-
crease in corneal nerve fiber length. This observation correlated with 
nerve regeneration (Ferdousi et al., 2015).
Nociceptive- evoked potentials (laser- evoked potentials and contact 
heat- evoked potentials) are neurophysiological and noninvasive methods 
to evaluate the function of small fiber sensory pathways. This diagnos-
tic method contributes to the early detection of peripheral neuropathy. 
Latency and amplitude nociceptive- evoked potentials are associated 
with the density of intraepidermal nerve fibers. Nociceptive evoked po-
tentials with skin biopsy may be used in the diagnosis of painful neurop-
athy (Casanova- Molla, Grau- Junyent, Morales, & Valls- Solé, 2011).
Magnetic resonance neurography has also shown promise as a new 
diagnostic strategy bringing new insights into the pathophysiology of 
neuropathies. This method enables visualization of axonal and demye-
linating lesions and their localizations in the peripheral nervous system 
(Wessig, Bendszus, Reiners, & Pham, 2011).
9  | PHARMACOGENETIC TECHNIQUES
Pharmacogenetic techniques are used to identify genes that 
may be useful in identifying patients at higher risk of developing 
chemotherapy- induced peripheral neuropathies. Nowadays, many 
trials assessing the interaction between gene- and chemotherapy- 
induced peripheral neuropathy are conducted. Progressive DNA- 
adduct accumulation and inhibition of DNA repair pathways (e.g., 
extracellular signal- regulated kinase 1/2, c- Jun N- terminal kinase/
stress- activated protein kinase, and p38 mitogen- activated protein 
kinase) are the main reasons for peripheral nerve and dorsal root gan-
glia neuron damage during cisplatin and carboplatin therapy. In case 
of oxaliplatin, polymorphisms of genes affecting the activity of pivotal 
metal transporters or voltage- gated sodium channel genes (e.g., or-
ganic cation transporters, organic cation/carnitine transporters, and 
some metal transporters, such as copper transporters and multidrug 
resistance- associated proteins) increase oxaliplatin neurotoxicity and 
treatment response (Avan et al., 2015). A Japanese study of colorec-
tal cancer patients treated with oxaliplatin- based chemotherapy es-
timated the pharmacogenetic correlation between neuropathy and 
polymorphisms of the excision repair cross- complementation Group 1 
(ERCC1) and glutathione- S- transferases pi 1 (GSTP1) genes. The study 
revealed that polymorphisms of ERCC1, C118T, and GSTP1 Ile105Val 
made patients more susceptible to oxaliplatin- induced neuropathy 
(Inada et al., 2010). Patients carrying CYP3A4 defective variants 
had more severe neuropathy and higher probability of neuropathy- 
induced paclitaxel treatment modifications; hence, CYP3A4 defective 
variants are a genetic marker associated with paclitaxel treatment 
modifications caused by neuropathy (Apellaniz- Ruiz et al., 2015).
10  | CHEMOTHERAPY- INDUCED 
NEUROPATHIES—WHAT CAN WE DO?
As discussed here, a large body of evidence suggests that 
chemotherapy- induced neuropathies are highly prevalent among 
cancer patients, constituting a major problem both for cancer pa-
tients and survivors as well as for their health care providers. The 
important question arises—is it possible to prevent and/or alleviate 
chemotherapy- induced neuropathy symptoms without jeopardizing 
cancer treatment regimens and incurring additional treatment costs? 
The answer should be affirmative. It is possible to reduce the num-
ber of chemotherapy- induced neuropathies and lower their financial 
burden on patients and health care provides, but in order to do so ef-
ficiently, we would need to revise patient examination and treatment 
protocols. Revised protocols should reflect our knowledge of chemo-
therapeutic neurotoxicity and encourage larger involvement of pri-
mary care physicians and neurologists in cancer treatment protocols.
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TABLE  2 Randomized controlled trials concerning prevention and treatment of chemotherapy- induced peripheral neuropathy according to 
Brami, Bao, and Deng (2016), with modifications 
Author (year) 
no. of patients Intervention Chemotherapy regimen Results (neurotoxicity)
Argyriou et al. (2006) 
n = 14
Alpha- tocopherol 300 mg bid 
during + up to 3 months post chth
Cisplatin Vitamin E 21.4% vs. control 68.5%
Argyriou et al. (2006) 
n = 16
Synthetic DL- alpha- tocopherol 
acetate 300 mg bid during + up to 
3 months post chth
Paclitaxel Vitamin E 18.7% vs. control 62.5%
Pace et al. (2010) 
n = 17
Alpha- tocopherol 400 mg bid before 
chth (median 3 months)  + 3 months 
after chth
Cisplatin Vitamin E 5.9% vs. placebo 41.7%
Kottschade et al. (2011) 
n = 96
DL- alpha- tocopherol 400 mg bid 
during + 1 month after chth
Taxanes, cisplatin, 
carboplatin, oxaliplatin, 
combinations of taxanes
Vitamin E 34% vs. 29% placebo
Afonseca et al. (2013) 
n = 18
Alpha- tocopherol 400 mg/day, 5 days 
before until chth completion
Oxaliplatin Cumulative incidence: vitamin E 83% vs. 
placebo 68%
Wang et al. (2007) 
n = 42
Glutamine 15 g/bid for 7 days 2 
weekly + usual care starting chth day 
1, day 42
Oxaliplatin Neurotoxicity G1 after 2 cycles: glutamine 
16.7% vs. control 38.4%, G3- 4 after 4 cycles: 
glutamine 4.8% vs. control 18.2%, G3- 4 after 
6 cycles: glutamine 11.9% vs. control 31.8%
Loven et al. (2009) 
n = 23
Glutamine 500 mg t.i.d throughout 
chth to 3 weeks after completion 
treatment
Paclitaxel + carboplatin No significant differences, but neurotoxicity 
presented with lower severity in glutamine 
group vs. placebo
Nishioka et al. (2011) 
n = 22
Goshajinkigan (GJG) 7.5 g/daily 
throughout chth
Oxaliplatin Neurotoxicity G3: GJG 0% vs. control 12%
Kono et al. (2013) 
n = 44
Goshajinkigan 7.5 g/daily for 26 weeks 
from chth start
Oxaliplatin The incidence of neurotoxicity G2 or greater 
after 8 cycles: GJG 39% vs. placebo 51%
Hershman et al. (2013) 
n = 208
Acetyl- L- carnitine 3000 mg/daily for 
24 weeks
Taxanes Acetyl- L- carnitine significantly increases 
neurotoxicity by 24 weeks of treatment
Guo et al. (2014) 
n = 122
Alpha lipoic acid 1800 mg/daily for 
24 weeks except 2 days prior 
– 4 days after chth
Platinum derivatives No differences between groups (alpha lipoic 
acid vs. placebo)
Ghoreishi et al. (2012) 
n = 35
Omega 3 fatty acids 640 mg t.i.d 
during chth + 1 month after chth
Paclitaxel Omega 3 fatty acids lowers neuropathy by 
70%
Rostock et al. (2013) Electroacupuncture, n = 14, hydroelec-
tric baths, n = 14, vitamin B1 300 mg/
daily/B6 300 mg/daily, n = 15, 
placebo, n = 17,
Taxanes, alkaloids vinca, 
platinum derivatives
No differences between groups
Rao et al. (2007) 
n = 50
Pregabalin (target dose 2700 mg daily) Paclitaxel, docetaxel, 
cisplatin, carboplatin, 
oxaliplatin, vincristine, 
vinblastine
No significant differences between study arm 
(pregabalin vs. placebo)
Shinde et al. (2016) 
n = 23
Pregabalin 75 mg bid within 12 weeks 
of chth
Paclitaxel No significant differences between study arm 
(pregabalin vs. placebo)
Cascinu et al. (2002) 
n = 21
Glutathione 1500 mg/m2 before 
oxaliplatin
Oxaliplatin Neurotoxicity G2- G4 after 12 cycles: three 
patients in glutathione group vs. eight in 
placebo group
Milla et al. (2009) 
n = 27
Glutathione 1500 mg/m2 before 
oxaliplatin
Oxaliplatin Significant reduction of neurotoxicity in 
glutathione group vs. placebo
Smyth et al. (1997) 
n = 74
Glutathione 3 g/m2 before cisplatin Cisplatin Neurosensory toxicity: 39% in glutathione 
group vs. 49% in control group; neuromotor 
toxicity: 9% in glutathione group vs. 12% in 
control group
Yang et al. (2012) 
n = 39
Duloxetine 30 mg/daily to 60 mg/daily Oxaliplatin 63.3% patients had a VAS score improvement 
and grade of neurotoxicity improvement
(Continues)
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The most important studies concerning preventions and treatment 
of chemotherapy- induced peripheral neuropathy, which have been 
conducted so far, are presented in Table 2. Not only working therapies, 
but also failed treatment of chemotherapy- induced peripheral neurop-
athy has been included in the table. Patients should be encouraged to 
report any signs of neuropathic pain, alteration in sensory perception, 
tingling, numbness, burning, increased hot/cold sensitivity, and motor 
dysfunctions (altered gait, difficulties with walking) as early as possi-
ble. Additionally, if known neurotoxic chemotherapeutics are used, a 
neurological examination with electrophysiological evaluation should 
be implemented early in the course of treatment; so, both patients and 
physicians would be better prepared to cope with possible neurotoxic 
effects. The use of neurotoxic chemotherapeutics should be closely 
monitored and if clinically permitted, that is, if a patient shows signs 
of cancer regression, drug doses should be reduced or combined with 
other less neurotoxic anti- cancer medication. If not counteractive, the 
use of over the counter antineuropathic supplements such as calcium 
or magnesium might be encouraged. If physically possible, patients 
should also be encouraged to exercise regularly and avoid factors that 
might increase nerve damage such as excessive drinking, smoking, or 
sitting in a cramped position.
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